Claims for Patent: 7,182,961

Summary for Patent: 7,182,961

Title:	Particulate compositions for pulmonary delivery
Abstract:	This invention concerns an improved particulate composition for delivering a drug to the pulmonary system. Applicants disclose a method of identifying an optimal form of aerodynamically light particles which are highly dispersible. The particles of the instant invention are made by creating hollow, spherical drug particles (i.e., progenitor particles) that collapse in the process of particle formation, leading to wrinkled, thin-walled drug particles of very low envelope density. Additionally, Applicants have found that such particles are especially optimal for inhaled aerosols when the surface area parameter (.sigma.) is greater than 2, optimally greater than 3.
Inventor(s):	Batycky; Richard P. (Newton, MA), Edwards; David A. (Boston, MA), Lipp; Michael M. (Framingham, MA)
Assignee:	Advanced Inhalation Research, Inc. (Cambridge, MA)
Application Number:	10/300,657
Patent Claims:	1. A particulate composition for delivery to the pulmonary system comprising particles having a tap density of less than 0.4 g/cm.sup.3 and a median geometric diameter greater than about 5 .mu.m, and an external surface area greater than about 5 m.sup.2/g wherein the particles have a continuous collapsed hollow sphere wall. 2. The particulate composition of claim 1 further comprising a drug. 3. The particulate composition of claim 2 further comprising a pharmaceutical excipient. 4. The particulate composition of claim 1 further comprising a dispersibility ratio of median geometric diameters of between about 1.0 to about 1.5 as measured by laser diffraction (RODOS/HELOS system). 5. The particulate composition of claim 1 having a surface area factor of greater than 2. 6. The particulate composition of claim 1 having a surface area factor of greater than 3. 7. The particulate composition of claim 1, wherein the external surface area is greater than about 8 m.sup.2/g. 8. The particulate composition of claim 1, wherein the external surface area is greater than about 10 m.sup.2/g. 9. The particulate composition of claim 1, wherein the tap density is less than 0.1 g/cm.sup.3. 10. A particulate composition for delivery to the pulmonary system comprising particles having a tap density of less than 0.4 g/cm.sup.3 and a median geometric diameter greater than about 5 .mu.m, and an external surface area greater than about 5 m.sup.2/g and a skeletal density of at least about 1 g/cm.sup.3. 11. The particulate composition of claim 10 further comprising a drug. 12. The particulate composition of claim 11 further comprising a pharmaceutical excipient. 13. The particulate composition of claim 10 further comprising a dispersibility ratio of median geometric diameters of between about 1.0 to about 1.5 as measured by laser diffraction (RODOS/HELOS system). 14. The particulate composition of claim 10 having a surface area factor of greater than 2. 15. The particulate composition of claim 10 having a surface area factor of greater than 3. 16. The particulate composition of claim 10, wherein the particles have a continuous collapsed hollow sphere wall. 17. The particulate composition of claim 10, wherein the external surface area is greater than about 8 m.sup.2/g. 18. The particulate composition of claim 10, wherein the external surface area is greater than about 10 m.sup.2/g. 19. The particulate composition of claim 10, wherein the tap density is less than 0.1 g/cm.sup.3. 20. A particulate composition for delivery of a drug to the pulmonary system comprising particles having a tap density of less than 0.4 g/cm.sup.3 and a geometric diameter greater than about 5 .mu.m, said particles having a continuous collapsed hollow sphere wall, said wall having a wall thickness less than about 150 nanometers and an external surface area of at least about 5 m.sup.2/g. 21. The particulate composition of claim 20, wherein at least 70% of the particles have a fine particle fraction of less than about 5.6 .mu.m. 22. The particulate composition of claim 20 having a surface area factor of greater than 2. 23. The particulate composition of claim 20 having a surface area factor of greater than 3. 24. The particulate composition of claim 20, wherein the external surface area is greater than about 8 m.sup.2/g. 25. The particulate composition of claim 20, wherein the external surface area is greater than about 10 m.sup.2/g. 26. The particulate composition of claim 20, wherein the tap density is less than 0.1 g/cm.sup.3. 27. A method of administering a product to the pulmonary system of an individual comprising the step of inhaling the composition of claim 20. 28. A particulate composition for delivery of a drug to the pulmonary system comprising particles having: (a) a tap density of less than 0.1 g/cm.sup.3, (b) a geometric diameter greater than about 5 .mu.m; (c) an external surface area of at least about 8 m.sup.2/g; (d) a surface area parameter of greater than 3; (e) at least 70% of the particles have a fine particle fraction of less than about 5.6 .mu.m; and (f) a continuous collapsed hollow sphere wall, said wall having a wall thickness less than about 150 nanometers. 29. A method of administering a product to the pulmonary system of an individual comprising the step of inhaling the composition of claim 28.